CRS
[용어속성] Compound
Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19
Clinical Trial
[키워드] average
C-reactive protein (CRP
complication of COVID-19
COVID-19
Critically ill
CRP
CRS
cytokine
Cytokine release syndrome
demonstrated
determine
Efficacy
eight
GM-CSF
Hypothesis
IFNγ
IL-10
IL-6
IL-8
improving oxygenation
majority
mechanically ventilated patient
mechanically ventilated patients
non-ventilated patients
Oxygen requirement
Oxygenation
oxygenation index
P/F
P/F ratio
paO2/fiO2
Patient
patient safety
patients
pharmacologic agent
pilot study
plasma
reducing
reduction in
reductions in
respiratory
Respiratory failure
resulting
Serum level
study period
subset
supplemental oxygen
syndrome
Therapeutic benefit
Therapeutic plasma exchange
TNFα
TPE
Treatment
Trial
Volume
was measured
were measured
[DOI] 10.1016/j.rmed.2020.106188 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.rmed.2020.106188 PMC 바로가기 [Article Type] Clinical Trial
Transaminases are Potential Biomarkers of Disease Severity in COVID-19 Patients: A Single-Center Experience
Internal Medicine
[키워드] 95% CI
acute respiratory syndrome
adjusted odds ratio
Admission
Analysis
analyzed
Aspartate aminotransferase
AST
baseline
chi-square test
clinical implication
Comorbidities
coronavirus
coronavirus disease
coronavirus disease-2019
COVID-19
COVID-19 patient
COVID-19 patients
CRS
Cytokine release syndrome
elevated
experience
Gastrointestinal
GI symptom
hepatic manifestations
higher risk
Hospitalization
identify
increased risk
Kruskal-Wallis
Logistic regression analysis
manifestation
mechanical ventilation
Mortality
multivariate
outcomes
Patient
patients with COVID-19
Pearson
Potential
predictor
SARS- CoV2
SARS-CoV2
Spread
study groups
the median
total bilirubin
transaminase
transaminitis
two group
variables
was performed
were used
[DOI] 10.7759/cureus.11555 PMC 바로가기 [Article Type] Internal Medicine
[DOI] 10.7759/cureus.11555 PMC 바로가기 [Article Type] Internal Medicine
Acute Limb Ischemia: A Rare Complication of COVID-19
Cardiac/Thoracic/Vascular Surgery
[키워드] 48 hour
Above-knee amputation
acute respiratory syndrome
Admission
Antibiotics
anticoagulation
arteriosclerosis obliterans
C-reactive protein
Care
Chest
Complication
concomitant use
coronavirus
cough
COVID-19
CRS
Cytokine release syndrome
Cytokines
D-dimer
Day
decrease
discharged
effective
elevated
Fever
hospital
hypertension
hypothermia
International
leukocyte
limb
lower limb
male
multivitamins
non-invasive ventilation
normalized
observation
oxygen
Pain
Patient
Peripheral pulse
polymerase chain
popliteal
positive
Prednisone
presenting
Prophylactic
SARS-CoV-2
severity
Shortness of breath
surgery
TCZ
tested
therapy
Thromboembolism
Tocilizumab
Vascular
Venous thrombosis
was done
[DOI] 10.7759/cureus.11488 PMC 바로가기 [Article Type] Cardiac/Thoracic/Vascular Surgery
[DOI] 10.7759/cureus.11488 PMC 바로가기 [Article Type] Cardiac/Thoracic/Vascular Surgery
Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients
Article
[키워드] absence
Admission
Analysis
appear
approach
ARDS
assessment
caused
Clinical course
Cohort
Course
courses
COVID-19
COVID-19 patient
criteria
Critically ill
CRS
Cytokine release syndrome
Cytokines
death
declining
Diagnostic Criteria
discharge
dominant
feature
Fever
HLH
hyperinflammation
Hyperinflammatory
ICU
immunology
immunosuppressive
implication
IMPROVE
independent
Infection
Inflammation
Innate immune cells
Innate immunity
macrophage activation syndrome
median
neutrophil
neutrophilic
observation period
outcomes
over
Patient
reached
Respiratory failure
secondary hemophagocytic lymphohistiocytosis
severe disease
sHLH
subgroups of patient
syndrome
tested
therapy
Trajectories
Treatment
virus
were assessed
[DOI] 10.1038/s41598-020-75260-w PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-020-75260-w PMC 바로가기 [Article Type] Article
Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
Medicine
[키워드] clinical benefit
Clinical guidelines
clinical trial
COVID-19
COVID-19 disease
COVID-19 patients
critical COVID-19 patient
CRS
Cytokine release syndrome
double-blinded
effective
elevated
Evidence
Health Service
Hospital stay
IL-6
IL-6R
Impact
inhibitor
interleukin-6
international public health
mechanism
Mortality
need for oxygen
pathology
Randomized
reduce
reducing
Release
SARS-CoV-2
severe COVID-19 patient
severe COVID-19 patients
shown
STOP
Symptoms
syndrome
TCZ
tension
therapy
Tocilizumab
treat
Treatment
Vaccine
while
[DOI] 10.3389/fmed.2020.571597 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2020.571597 PMC 바로가기 [Article Type] Medicine
Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
Review
[키워드] acute respiratory distress
acute respiratory syndrome
alveolar epithelial cell
ARDS
cause
caused
Cell
clinical trial
clinical trials
coronavirus
Coronavirus disease 2019
COVID‐19
COVID‐19 patient
COVID‐19
CRS
Cytokine release syndrome
Cytokines
derivative
Efficacy
endothelial
Exosomes
Factor
Factors
FGF
fibroblast
function
growth
hearts
HGF
illnesses
immune cells
immune system
KGF
lung
Mesenchymal stem cells
MSC
MSCs
MSCs therapy
Necrosis
other organ
paracrine
Pathogenesis
pathogenic
Patient
potential mechanism
Potential treatment
preclinical studies
preclinical study
progression
promote
PROTECT
Protein
pulmonary fibrosis
quantified
Registered
regulate
respiratory infectious disease
SARS‐CoV‐2
secrete
secreting
secretion
shown
stem cell
Stem cell therapy
suggested
supportive care
syndrome
the disease
therapeutic
therapeutic potential
therapy
tissue repair
TNF‐α
Treatment
variety
Vascular
VEGF
[DOI] 10.1111/cpr.12939 PMC 바로가기 [Article Type] Review
[DOI] 10.1111/cpr.12939 PMC 바로가기 [Article Type] Review
Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients
COVID19 and Transplantation (R Avery, Section Editor)
[키워드] absence
administration
Anecdotal
anti-IL-1
anti-IL-6
appear
bacterial superinfection
baseline
benefit
canakinumab
Case series
characterized
clinical benefit
clinical experience
cohort study
Colchicine
control group
coronavirus disease
Corticosteroid
COVID-19
CRS
cytokine
Cytokine release syndrome
Deleterious
Efficacy and safety
Evidence
finding
heterogeneity
Hyperinflammatory
immunomodulation
immunomodulatory therapy
Immunosuppression
inhibitor
Interpretation
kidney
lack
limit
management
monoclonal
NLRP3 inflammasome
non-transplant patients
observational study
Patient
pleiotropic
Pneumonia
randomized clinical trial
RCT
recent
recipient
reported
review
Safe
shown
Solid
solid organ transplantation
SOT
survival
therapeutic strategy
tissue damage
Tocilizumab
tocilizumab therapy
Transplant
with COVID-19
[DOI] 10.1007/s40472-020-00306-x PMC 바로가기 [Article Type] COVID19 and Transplantation (R Avery, Section Editor)
[DOI] 10.1007/s40472-020-00306-x PMC 바로가기 [Article Type] COVID19 and Transplantation (R Avery, Section Editor)
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents
Review
[키워드] activated
acute respiratory distress
acute respiratory distress syndrome
alveolar macrophage
angiotensin converting enzyme 2
antibody
Antiviral
article
B cell
bind
blunt
caused
characterized
China
Chloroquine
Combination
coronavirus 2
Coronavirus disease 2019
COVID-19
COVID-19 illness
CRS
cytokine
Cytokine release syndrome
Cytokine storm
drug target
dysregulation
enzyme
epithelial cells
Fever
global pandemic
hemodynamic instability
hypoxia
identify
IFN
IL-1β
immune system
immunological mechanism
Immunotherapy
imperative
Innate immunity
involved
manifestation
Necrosis
Novel coronavirus
nuclear
Obstetric
organ damage
overcome
Pathogenesis
pathophysiology
Patient
pediatric
Phase 2
Phase 3
receptor
reduce
respiratory
respiratory symptoms
responsible
resulting
SARS-CoV-2
SARS-CoV-2 epidemiology
severe COVID-19
Signaling
syndrome
therapeutic agent
therapeutic interventions
tissue injury
TLR
Tocilizumab
triggering
Viral load
viral replication
virus
Virus-host interaction
Virus-host interactions
World Health Organization
worsening
[DOI] 10.1186/s12985-020-01415-w PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s12985-020-01415-w PMC 바로가기 [Article Type] Review
A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19
Article
[키워드] acute respiratory disease
adverse outcome
Analysis
caused
checked
China
Cholinergic anti-inflammatory pathway
country
COVID-19
CRS
current
current smokers
Cytokine release syndrome
Cytokine release syndrome (CRS)
epidemiological
Epidemiological study
Evidence
expected
hospitalised
Infection
initial
Italy
less
literature review
many cases
mechanism
Meta-analysis
much lower
New coronavirus
Nicotine
offer
Patient
percentage
Prevalence
progression
review
SARS-CoV-2
smoker
smoking
statistically
statistically significant difference
USA
World Health Organization
worldwide pandemic
[DOI] 10.3390/ijerph17207394 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/ijerph17207394 PMC 바로가기 [Article Type] Article